Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Optinose Inc Market Cap
Based on ratings from 4 stock analysts, the Optinose Inc stock price is expected to increase by 488.24% in 12 months. This is calculated by using the average 12-month stock price forecast for Optinose Inc. The lowest target is $1 and the highest is $5. Please note analyst price targets are not guaranteed and could be missed completely.
Optinose Inc has a total of 4 Wall St Analyst ratings. There are 4 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Optinose Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of OPTN.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| David Amsellem Piper Sandler | Overweight | $1 | Maintains | Nov 13, 2024 |
| Matthew Caufield HC Wainwright & Co. | Buy | $5 | Reiterates | Nov 13, 2024 |
| Thomas Flaten Lake Street | Buy | $3 | Maintains | May 15, 2024 |
| Matthew Caufield HC Wainwright & Co. | Buy | $5 | Reiterates | May 15, 2024 |
| Matthew Caufield HC Wainwright & Co. | Buy | $5 | Reiterates | Apr 29, 2024 |
| Thomas Flaten Lake Street | Buy | $4 | Maintains | Mar 18, 2024 |
| Matthew Caufield HC Wainwright & Co. | Buy | $5 | Reiterates | Mar 18, 2024 |
| Matthew Caufield HC Wainwright & Co. | Buy | $5 | Initiates | Mar 11, 2024 |
| Thomas Flaten Lake Street | Buy | $3 | Initiates | Aug 21, 2023 |
Piper Sandler | Overweight | Maintains | Aug 11, 2023 | |
| Gary Nachman BMO Capital | Outperform | $5 | Maintains | Nov 14, 2022 |
| Glen Santangelo Jefferies | Buy | $5 | Assumes | Oct 21, 2022 |
| Brandon Folkes Cantor Fitzgerald | Overweight | $21 | Reiterates | Mar 5, 2020 |
Cowen & Co. | Outperform | Initiates | Dec 18, 2019 | |
BMO Capital | Outperform | $24 | Maintains | Aug 13, 2019 |
Cantor Fitzgerald | Overweight | $27 | Maintains | Nov 14, 2018 |
| Gary Nachman BMO Capital | Outperform | $28 | Maintains | Aug 15, 2018 |
Cantor Fitzgerald | Overweight | Initiates | Aug 8, 2018 | |
RBC Capital | Outperform | Initiates | Nov 7, 2017 | |
Jefferies | Buy | Initiates | Nov 7, 2017 |
When did it IPO
2017
Staff Count
132
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers - Specialty & Generic
CEO
Dr. Ramy A. Mahmoud M.D., M.P.H.
Market Cap
$76.4M
In 2023, OPTN generated $71.0M in revenue, which was a decrease of -6.93% from the previous year. This can be seen as a signal that OPTN's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 02 Dec 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Optinose (NASDAQ:OPTN) will present a company overview and business update at the Piper Sandler Healthcare Conference on December 5, 2024, at 1:30 p.m. ET.
Why It Matters - Optinose's management presentation may signal strategic updates or new developments, potentially impacting stock performance and investor sentiment in the pharmaceutical sector.
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - OptiNose, Inc. (NASDAQ:OPTN) will hold its Q3 2024 earnings conference call on November 12, 2024, at 8:00 AM ET, featuring key executives and analysts.
Why It Matters - OptiNose's upcoming earnings call will provide insights into its financial performance and strategic direction, influencing investor sentiment and stock valuation.
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - In Q3 2024, the company reported XHANCE net revenue of $20.4 million, marking a 3% increase from Q3 2023.
Why It Matters - The 3% revenue growth for XHANCE signals stable demand and potential for future profitability, which may positively influence investor confidence and stock performance.
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - OptiNose (OPTN) reported break-even quarterly EPS, exceeding the Zacks Consensus Estimate of a loss of $0.05, and improved from a loss of $0.08 per share a year earlier.
Why It Matters - OptiNose's break-even earnings exceed expectations, signaling potential profitability and improved financial health, which may boost investor confidence and drive stock performance.
Tue, 05 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - A conference call and webcast will take place on November 12, 2024, at 8:00 a.m. Eastern Time.
Why It Matters - The scheduled conference call and webcast may provide insights into company performance, strategic direction, and future outlook, influencing investment decisions.
Wed, 16 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - OptiNose, Inc. granted 185,000 stock options to eight new employees as inducement for employment, outside its 2010 Stock Incentive Plan, per Nasdaq rules.
Why It Matters - OptiNose's grant of stock options indicates growth and recruitment efforts, potentially signaling confidence in future performance, which could influence stock valuation and investor sentiment.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
